Current status of cellular therapy for ischemic heart disease

Shafie Fazel, Gilbert H.L. Tang, Denis Angoulvant, Massimo Cimini, Richard D. Weisel, Ren Ke Li, Terrence M. Yau

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Cellular therapy for acute myocardial infarction and ischemic cardiomyopathy has entered clinical trials across the globe. Early promising results have now provided the justification for larger randomized and blinded trials to address the efficacy of cellular therapy. A variety of fresh or cultured autologous cells have been delivered by catheter-guided endocardial, catheter-guided intracoronary, catheter-guided transvenous, and direct epicardial routes. This review will summarize the clinical data and highlight salient basic science data that support the ongoing efforts to identify the optimal cellular therapy both for acute myocardial infarction and chronic ischemic cardiomyopathy patients.

Original languageEnglish
Pages (from-to)S2238-S2247
JournalAnnals of Thoracic Surgery
Issue number6
StatePublished - Jun 2005


Dive into the research topics of 'Current status of cellular therapy for ischemic heart disease'. Together they form a unique fingerprint.

Cite this